[
  {
    "ts": "2025-09-16T18:58:24+00:00",
    "headline": "What Do Analysts Think About Amgen Inc. (AMGN)?",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best drug stocks to buy right now. Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with total revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues. In […]",
    "url": "https://finance.yahoo.com/news/analysts-think-amgen-inc-amgn-185824691.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3ba12da4-8b93-374f-8896-8a96de1b133d",
      "content": {
        "id": "3ba12da4-8b93-374f-8896-8a96de1b133d",
        "contentType": "STORY",
        "title": "What Do Analysts Think About Amgen Inc. (AMGN)?",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best drug stocks to buy right now. Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with total revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues. In […]",
        "pubDate": "2025-09-16T18:58:24Z",
        "displayTime": "2025-09-16T18:58:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Dogs of the Dow: Why Amgen’s (AMGN) Dividend Power Makes it a Standout Pick",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fl9k_iPg0JyfVI.qZJRd8A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RgojEqpZ8ITlaPGpQimL8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-amgen-inc-amgn-185824691.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-amgen-inc-amgn-185824691.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-16T16:58:00+00:00",
    "headline": "AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?",
    "summary": "Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.",
    "url": "https://finance.yahoo.com/news/amgn-vs-vktx-biotech-stock-165800833.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9f5f6cd0-776c-3e7e-af1b-fb8438dd05e9",
      "content": {
        "id": "9f5f6cd0-776c-3e7e-af1b-fb8438dd05e9",
        "contentType": "STORY",
        "title": "AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?",
        "description": "",
        "summary": "Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.",
        "pubDate": "2025-09-16T16:58:00Z",
        "displayTime": "2025-09-16T16:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgn-vs-vktx-biotech-stock-165800833.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgn-vs-vktx-biotech-stock-165800833.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-16T14:00:21+00:00",
    "headline": "Amgen Insiders Sold US$12m Of Shares Suggesting Hesitancy",
    "summary": "Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...",
    "url": "https://finance.yahoo.com/news/amgen-insiders-sold-us-12m-140021934.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "95fa3b12-0ee5-3d10-8340-1342eddac36d",
      "content": {
        "id": "95fa3b12-0ee5-3d10-8340-1342eddac36d",
        "contentType": "STORY",
        "title": "Amgen Insiders Sold US$12m Of Shares Suggesting Hesitancy",
        "description": "",
        "summary": "Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...",
        "pubDate": "2025-09-16T14:00:21Z",
        "displayTime": "2025-09-16T14:00:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-insiders-sold-us-12m-140021934.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-insiders-sold-us-12m-140021934.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-16T11:03:52+00:00",
    "headline": "Drug developer Dualitas launches $65 million funding round",
    "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
    "url": "https://ca.finance.yahoo.com/news/drug-developer-dualitas-launches-65-110352501.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "ff359b0a-1fad-3066-906a-bded53976088",
      "content": {
        "id": "ff359b0a-1fad-3066-906a-bded53976088",
        "contentType": "STORY",
        "title": "Drug developer Dualitas launches $65 million funding round",
        "description": "",
        "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
        "pubDate": "2025-09-16T11:03:52Z",
        "displayTime": "2025-09-16T11:03:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/drug-developer-dualitas-launches-65-110352501.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/drug-developer-dualitas-launches-65-110352501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "ROG.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-16T11:00:00+00:00",
    "headline": "Immuneering Appoints Dr. Thomas Schall as Chairman of the Board",
    "summary": "Thomas Schall Thomas Schall, Chariman of the Board of Directors of Immuneering NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder",
    "url": "https://finance.yahoo.com/news/immuneering-appoints-dr-thomas-schall-110000789.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "491ffb67-779e-3c9a-816f-748adbaae9f5",
      "content": {
        "id": "491ffb67-779e-3c9a-816f-748adbaae9f5",
        "contentType": "STORY",
        "title": "Immuneering Appoints Dr. Thomas Schall as Chairman of the Board",
        "description": "",
        "summary": "Thomas Schall Thomas Schall, Chariman of the Board of Directors of Immuneering NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder",
        "pubDate": "2025-09-16T11:00:00Z",
        "displayTime": "2025-09-16T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/8193fece5a3f61a8538a9457edc4cd8a",
          "originalWidth": 510,
          "originalHeight": 500,
          "caption": "Thomas Schall, Chariman of the Board of Directors of Immuneering",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KhkwSqh3NAQsyA810b1.Eg--~B/aD01MDA7dz01MTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8193fece5a3f61a8538a9457edc4cd8a.cf.webp",
              "width": 510,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kBhs7FgYZ95tFApeIdEBvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8193fece5a3f61a8538a9457edc4cd8a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immuneering-appoints-dr-thomas-schall-110000789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immuneering-appoints-dr-thomas-schall-110000789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IMRX"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]